Pharmafile Logo

How to elevate your communications testing with AI powered insights and analytics

Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers

Pharmaceutical companies strive to develop the most effective communication assets for their brands in order to maximise their impact. The challenge though is in identifying the messages and concepts that will have the greatest impact and influence with customers.

While there is now an appreciation of the subconscious behavioural biases that influence how we respond to marketing, many pharmaceutical companies are still developing and testing the majority of their communication campaigns based on more traditional insight gathering.

At Research Partnership, we have developed a behavioural science-led framework incorporating new AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers. watch this webcast to learn about the various components of this new approach and how each of them offered complementary benefits for a recent client who was looking to evaluate their creative concepts.

What you will learn

  • How innovative new technologies can complement traditional research techniques to provide a truer, multi-dimensional picture of how marketing communications perform with the target audience
  • How a new, behavioural science-led approach to communications research can take into account both instinctive and considered thinking as well as other behavioural biases to provide a more holistic evaluation of marketing materials
  • How to make use of AI, facial analysis and implicit response techniques to gain a 360-degree view of communications performance and how this can overcome the limitations of conducting market research remotely in a post-pandemic era

Watch the webcast

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Forever Angels founder is awarded an MBE

We are delighted to announce that Forever Angels founder Amy Hathaway has been awarded an MBE in this year’s Queen’s Birthday Honours list for providing interim and community care to...

Research Partnership’s Singapore team relocates to new office

We are delighted to announce that our Asia-Pacific team in Singapore has relocated to new premises.

Nutrition Market in Brazil: Growth Against the Odds

Published in eyeforpharma June 2017 by Marc Yates

Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report

Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...

Research Partnership is celebrating 20 years in business

Watch our short video to see how we have grown. Please note the video comes with some fun, themed music. https://www.researchpartnership.com/news/2017/06/research-partnership-is-celebrating-20-years-in-bus...

Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in...

Research Partnership announces several new appointments

Research Partnership is delighted to welcome Anne Cunningham and Morten Andersen and announce that Sue Rees has joined our specialist Emerging Markets team.

PMRC San Francisco 2017

We are delighted to be presenting a paper and exhibiting at the Pharmaceutical Market Research Conference 13-14 June in Bay Area close to our new office in San Francisco.Representing Research...

EphMRA Annual Conference 2017

Visit us on stand number 14

Richard Head nominated for EphMRA Award

We are delighted to announce that Research Partnership’s Director Richard Head has been nominated for The EphMRA President’s Award for Contribution to Pharmaceutical Market Research.According to EphMRA, Richard has been...